[
  {
    "ts": "2025-12-20T10:06:09+00:00",
    "headline": "Is Pfizer A Recovery Opportunity After Covid Vaccine Boom Fades?",
    "summary": "If you are wondering whether Pfizer at around $25 a share is a value trap or a genuine opportunity, this breakdown will help you decide whether it deserves a spot on your watchlist right now. Despite a tough few years, the stock has inched up about 2.5% over the last year, even though it is still down roughly 5.3% year to date and more than 40% over three years, a mix that often signals shifting expectations around risk and recovery potential. Recent attention has focused on how Pfizer is...",
    "url": "https://finance.yahoo.com/news/pfizer-recovery-opportunity-covid-vaccine-100609119.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "dfdcdfc3-4ea4-3415-97bc-71bbf5b2ee67",
      "content": {
        "id": "dfdcdfc3-4ea4-3415-97bc-71bbf5b2ee67",
        "contentType": "STORY",
        "title": "Is Pfizer A Recovery Opportunity After Covid Vaccine Boom Fades?",
        "description": "",
        "summary": "If you are wondering whether Pfizer at around $25 a share is a value trap or a genuine opportunity, this breakdown will help you decide whether it deserves a spot on your watchlist right now. Despite a tough few years, the stock has inched up about 2.5% over the last year, even though it is still down roughly 5.3% year to date and more than 40% over three years, a mix that often signals shifting expectations around risk and recovery potential. Recent attention has focused on how Pfizer is...",
        "pubDate": "2025-12-20T10:06:09Z",
        "displayTime": "2025-12-20T10:06:09Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QSfydsi7Q.1zNEN99DbEyw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hi2p7oczHh8yTJraqZcczg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-recovery-opportunity-covid-vaccine-100609119.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-recovery-opportunity-covid-vaccine-100609119.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]